Chemistry: molecular biology and microbiology – Micro-organism – per se ; compositions thereof; proces of... – Bacteria or actinomycetales; media therefor
Reexamination Certificate
2006-01-10
2006-01-10
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Micro-organism, per se ; compositions thereof; proces of...
Bacteria or actinomycetales; media therefor
C424S093410
Reexamination Certificate
active
06984513
ABSTRACT:
Recombinant anaerobic bacterial compositions that under anaerobic conditions present in a solid tumor and produce an enzyme capable of catalyzing the conversion of a prodrug to its cytotoxic product in situ are described. Methods of treating tumors using the composition are also described.
REFERENCES:
patent: 5633158 (1997-05-01), Anlezark et al.
patent: 6416754 (2002-07-01), Brown et al.
patent: 6652849 (2003-11-01), Brown et al.
patent: 228301 (1985-10-01), None
patent: WO 93/08288 (1993-04-01), None
Fox et al. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia Gene Therapy vol.3 pp. 173-178 1996 (cited by Applicant).
Lemmon et al. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment Gene Therapy vol. 4 pp. 791-796 1997 (cited by Applicant).
Liu et al. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia
ecrosis Proceedings of the American Association for Cancer Research vol. 41 Mar. 2000 (cited by Applicant).
Anlezark, et al.,Biochem. Pharmacol. 44:2289-2295, (1992).
Antoniw, et al.,Br. J. Cancer 62:909-914, (1990).
Bagshawe,Br. J. Cancer 60:275-281, (1989).
Boyd,Current therapy in Oncology, Decker et al., eds, pp. 11-22, (1992).
Bryant, et al.,J. Biol. Chem. 266:4126-4130, (1991).
*Davis, T.O., et al.,J. Mol. Microbiol. Biotechnol. 2(1):59-69, (2000).
Fitzgerald, et al.,Biochem. Soc. Trams. 20:731-734, (1992).
**Fox, M.E., et al.,Gene Therapy 3:173-178, (1996).
Graves, et al.,Proc. Natl. Acad. Sci. USA 82:1653-1657, (1985).
*Hamstra, D.A., et al.,Human Gene Therapy 10:1993-2003, (1999).
Jain,J. Natl. Cancer Inst. 81:570-576, (1989).
**Lemmon, M.J., et al.,Gene Therapy 4:791-796, (1997).
**Liu, et al.,Proceedings of the American Association Cancer Research 41:733-734, (Mar. 2000).
*Liu, S.C., et al.,Gene Therapy 9:291-296, (2002).
*Melton, R.G. and Sherwood, R.F.,J. Natl. Cancer Inst. 88(3/4):153-165, (1996).
*Minton, N.P., et al.,FEMS Microbiol. Lett. 17:357-364, (1995).
Mullen et al,Proc. Natl. Acad. Sci. USA 89:33-37, (1992).
*Niculescu-Duvaz, et al.,Anti-Cancer Drug Design 14:517-538, (1999).
Oultram, et al.,FEMS Microbiol. Lett. 56:83-88, (1988).
Rosenberg,JAMA 268:2416-2419, (1992).
Schlechte, et al.,Zbl. Bakt. Hyg. A268:347-356, (1988).
Senter,FASEB J. 4:188-193, (1990).
Thiele, et al.,Cancer Res. 24:234-238, (1964).
Watanabe, et al.,Nucleic Acid Res. 18:1059, (1990).
Brown John M.
Giaccia Amato J.
Liu Shie-Chau
Minton Nigel P.
Katcheves Konstantina
Ketter James
Perkins Coie LLP
The Board of Trustees of the Leland Stanford Junior University
LandOfFree
Anaerobe targeted enzyme-mediated prodrug therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anaerobe targeted enzyme-mediated prodrug therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anaerobe targeted enzyme-mediated prodrug therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3549820